跳至主要内容
临床试验/JPRN-UMIN000040948
JPRN-UMIN000040948招募中未知

A prospective study of the efficacy and safety of preoperative chemotherapy with gemcitabine+nab-paclitaxel therapy for resectable pancreatic body and tail cancer with splenic arteriovenous invasion by image. - A prospective study of the efficacy and safety of preoperative chemotherapy for resectable pancreatic body and tail cancer with splenic arteriovenous invasion by image.

Wakayama medical university0 个研究点目标入组 49 人开始时间: 2020年7月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
49

研究概览

简要总结

暂无简介。

研究设计

研究类型
Others,meta-analysis etc

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Cases with a history of severe drug hypersensitivity or drug allergy 2. Cases with a history of malignant tumor 3. Cases with active infection 4. Patients with peripheral sensory neuropathy (Grade 2 or higher) 5. Cases with a history of interstitial pneumonia or pulmonary fibrosis 6. Patients with uncontrolled ascites or pleural effusion 7. Cases with uncontrolled diabetes 8. Cases with Uncontrolled congestive heart failure, angina, hypertension, arrhythmia 9. Cases with history of neurologically or psychologically significant disease 10. Cases with diarrhea 11. Pregnant women, lactating women, and women who may be pregnant (will), or women and men who are not willing to contracept during the study period and for a certain period (180 days) after the last administration of study drug 12. Other cases that the doctor has determined to be unsuitable for participation in this clinical trial 13. Cases which conforms to Borderline Resectable/Unresectable of NCCN guidelines (Version 1.2020) by MDCT diagnosis. 14. Patients with active hepatitis B

研究者

相似试验